Skip to content

Home Exercise Intervention in Persons With Multiple Sclerosis

Exercise, Subclinical Atherosclerosis and Walking Mobility in Multiple Sclerosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01824550
Acronym
HOMS
Enrollment
59
Registered
2013-04-04
Start date
2012-11-13
Completion date
2018-09-07
Last updated
2019-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The objective of this study is to determine the effect of home-based, aerobic exercise training on subclinical atherosclerosis and mobility disability in persons with Multiple Sclerosis (MS). Our central hypothesis is that aerobic exercise training reduces both subclinical atherosclerosis and mobility disability.

Detailed description

This study will use a two-arm randomized control trial (RCT) design to examine the effect of a home-based exercise training program versus a minimal exercise, attention control condition on markers of subclinical atherosclerosis and mobility disability in persons with MS. The primary outcomes will be subclinical atherosclerosis including measures of arterial structure and function and measures of mobility disability including the six-minute walk and timed 25-foot walk, GaitRite walking assessment and one week of accelerometry data. Fifty-four persons with MS who have an Expanded Disability Status Score (EDSS) score between 0 and 4.0 will be randomized into either the home-based exercise training condition or the attention control condition. Participation in this study will include a 3-month exercise program to be completed at home. In addition, participants will need to come to University of Illinois at Chicago (UIC) three times to undergo testing. Each visit will take about 3-4 hours to complete. Testing that will take place during these three visits include blood pressure measurement, six vascular (artery) measurements, heart measurements, short walking tests, peak aerobic capacity test, blood draw, five quality of Life questionnaires and two cognitive function tests. The home-based exercise regimen will include cycle ergometry as an aerobic mode of training 3 times per week with a gradual progression of duration and intensity across a 12-week period. Exercise prescription will be based on the peak aerobic capacity cycling test conducted during the first visit. The attention control will involve stretching using the same frequency and duration across a 12-week period with exercises recommended by the National Multiple Sclerosis Society (NMSS). Both arms will receive weekly internet coaching sessions via video chatting. Subclinical atherosclerosis and mobility disability data will be collected before, after 6 weeks of training and immediately after the 12-week intervention.

Interventions

OTHERhome-based exercise training condition

Home based endurance exercise training

Sponsors

University of Illinois at Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* physically inactive * BMI\<40 * 1st stage of MS (i.e., defined as EDSS score of 0 - 4.0) * independently ambulatory (walking without an assistive device such as a cane or orthotic) * relapse free in the past 30 days * confirmed diagnosis of MS * asymptomatic (i.e., no underlying clinically diagnosed cardiovascular disease) * be on a stable disease modifying therapy * physician approval for undertaking exercise testing and training

Design outcomes

Primary

MeasureTime frameDescription
Subclinical atherosclerosis3 monthsThis will me measured through carotid intima media thickness, flow mediated dilation of forearm, and aortic pulse wave velocity

Secondary

MeasureTime frameDescription
Mobility disability3 monthsThis will be measured by the 6-min walk, 25 ft walk, the Get-up-and-go test and by gait characteristics.

Other

MeasureTime frameDescription
Disease state, and fatigue3 monthsThis will be measured via questionnaires

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026